Join CTTC | Print Page | Contact Us | Sign In
COVID-19

CTTC Response to COVID-19 (Update October 20, 2022)

The CTTC recommends using other major sources of information for timely information on the COVID-19 pandemic. Some of these may include:

CTTC Response to COVID-19 (Update August 15, 2022)

The CTTC recommendations surrounding COVID-19 have been updated. The major highlights of this update include:

  • An updated listing of COVID-19 vaccines approved in Canada
  • A recommendation for the use of Evusheld as a preventative measure in patients that are immunocompromised
  • A recommendation for the use of treatments that may speed up the recovery process for patients awaiting transplant that have COVID-19

Please click here to read the full CTTC Position Statement on COVID-19 [Revised August 15, 2022]

 

Please click here to read the full CTTC Position Statement on COVID-19 Vaccination [Revised August 15, 2022]

CTTC Response to COVID-19 (Update March 9, 2022)

The CTTC recommendations surrounding COVID-19 have been updated. The major highlights of this update include:

  • The recommendation for case-by-case evaluation regarding cryopreservation of donor PBSCs for unrelated donors
  • For COVID-positive donors, a deferral period of 14 days for asymptomatic or 14 days after recovery if symptomatic is recommended
  • For COVID-positive patients, centres may consider a shorter (14-day) deferral period if the need is urgent

 

Please click here to read the full CTTC Position Statement on COVID-19 [Revised March 9, 2022]


Please click here to read the full CTTC Position Statement on COVID-19 Vaccination [Revised November 3, 2021]

CTTC Response to COVID-19 (Update November 3, 2021)

The CTTC recommendations surrounding COVID-19 and vaccination have been updated. The major highlights of these updates are:

  • The choice to cryopreserve donor product or not is based on many factors and should be left up to each individual centre to decide.
  • Both the Pfizer and Moderna vaccines are approved for Canadians aged 12 and older, but their use in children aged 5-11 has not yet been approved by Health Canada.
  • Since the immune system is essentially reset after hematopoietic stem cell transplantation (HSCT), these patients should start a new course of vaccines post-transplant, including a third dose when possible.  Re- vaccination should start 3-6 months post-HSCT, at the discretion of each centre.

Please click here  to read the full CTTC Position Statement on COVID-19 [Revised November 3, 2021]


Please click here  to read the full CTTC Position Statement on COVID-19 Vaccination [Revised November 3, 2021]

CTTC Response to COVID-19 (Update August 24, 2021)

Author: Dr. K Paulson on behalf of the CTTC BMT Directors Committee

The CTTC recommendations surrounding COVID-19 vaccination have been updated. Highlights of this update:

  • Four vaccines are currently approved for use in Canadians aged 18 and over; Pfizer/BioNTech approved for children turning 12 this year
  • Immunocompromised patients are at high risk of poor outcomes if infected with COVID-19 and should be vaccinated, including receiving a third booster where available
  • Healthcare workers and caregivers should also get vaccinated to reduce the likelihood of transmission to BMT and cellular therapy recipients, and other immunocompromised individuals

Please click here to read the full CTTC Position Statement on COVID-19 [Revised August 24, 2021]

CTTC Response to COVID-19 (Update January 18, 2021)


Cell Therapy Transplant Canada
Position Statement on COVID-19 Vaccination
Latest Revision: January 18, 2021
Author: Dr. K Paulson on behalf of the CTTC BMT Directors Committee*
 
There are currently two Health Canada approved vaccines for COVID-19, both based on mRNA technology (tozinameran, developed by BioNTech and Pfizer, and mRNA-1273, developed by Moderna). Supplies are currently limited, and individual provinces are developing prioritization strategies based on recommendations from the National Advisory Committee on Immunization (NACI). NACI developed a suggested sequence of priorities, beginning with health care workers and the elderly, particularly those residing in long term care facilities, recognizing the need to protect those at highest risk of death. The mortality rate of COVID infection in patients that occur in the months following allogeneic transplant is comparable to residents of long term care facilities. The largest study to date of patients with hematologic malignancies, including recipients of stem cell transplant, found an overall mortality rate of 36%.1 Given that NACI recommended prioritizing vaccination to those at the highest risk of death from COVID, it would follow that a strategy to protect recipients of stem cell transplantation and cellular therapy would also be of the highest priority...

 

Please click here to read the full CTTC Position Statement on COVID-19 [Last Revision: January 18, 2021] in English

Please click here to read the full CTTC Position Statement on COVID-19 [Last Revision: January 18, 2021] in French

CTTC Response to COVID-19 (Update October 22, 2020)

CTTC is monitoring closely the rapidly evolving situation and is committed to engaging and supporting our membership. We have scheduled a series of virtual town halls, have  dedicated a web page to collate and aggregate position statements from other societies, and have an online forum for community discussion (CTTCanada.ca).

Please click here to read the full CTTC Position Statement on COVID-19 [Last Revision: October 22, 2020].

CTTC Response to COVID-19 (Update July 23, 2020)


Cell Therapy Transplant Canada is monitoring closely the rapidly evolving situation and is committed to engaging and supporting our membership.

We have scheduled a series of virtual town halls, have dedicated a web page to collate and aggregate position statements from other societies, and have an online forum for community discussion

Please click here to read the full CTTC Position Statement on COVID-19 [Last Revision: July 23, 2020].


For information from our partners, please click on the links below:


CTTC Forum

To facilitate discussion and engagement on this issue, CTTC has created a FORUM for members. We invite you to join the discussion.

 

Canadian Blood Services Stem Cell Registry & Cord Blood Bank

Click hereto access the File Library of supporting documents.

 

COVID-19-Related Guidelines and Supporting Documents

Click here to access the File Library of supporting documents.

 

CTTC Virtual Town Halls - March 17 & March 18, 2020

Click here to access the Town Hall recordings and presentation slide decks.

 

Ontime Onboard Courier GmbH

Since 2003 we have provided more than 30.000 accompanied HSC transports for many acknowledged Registries, Collection Centers and Transplant Centers worldwide. We offer services from and to every location on the globe, mainly delivering on the day of donation. Our goal is to create the best and fastest connection for each individual transport in order to contribute to the recovery of affected patients around the world. Our experience on all 6 continents serving more than 400 transplant centers guarantees the quality you are looking for. 24/7/365 – multi lingual staff – online tracking – we cover all your needs. onboard@ontimecourier.com or +49-89-357373-20 – contact us to find out more! 

Prompt response of our well-trained team concerning your request enables quick decisions on your part. 

 

 

This website is sponsored by an 
unrestricted educational grant from: